Targeted agents for cancer treatment during pregnancy

Matteo Lambertini, Fedro A. Peccatori, Hatem A. Azim

Research output: Contribution to journalArticle

Abstract

The last decade has witnessed important advances in the field of managing cancer during pregnancy. However, still limited data is available on the safety of administering targeted agents in pregnant cancer patients. Given the increasing use of targeted agents in clinical practice, it is becoming vital to properly understand how far they can be used in a pregnant patient without compromising the outcome of the fetus. Unlike chemotherapy, monoclonal antibodies are large molecules that require active transport via the placenta to reach the fetus. On the other hand, similarly to chemotherapy, small molecules like tyrosine kinase inhibitors (TKIs) can cross the placenta throughout the pregnancy period.The majority of targeted agents have worrying preclinical data discouraging their use during pregnancy. Multi-TKIs are of particular concern given their potential interference with other vital physiological functions that could be necessary in fetal development. Yet this does not mean that all targeted agents should be avoided completely during pregnancy. The current review provides a critical evaluation on all targeted agents that are currently in clinical use and provides a guide in order to help clinicians counseling their pregnant cancer patients.

Original languageEnglish
Pages (from-to)301-309
Number of pages9
JournalCancer Treatment Reviews
Volume41
Issue number4
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Pregnancy
Protein-Tyrosine Kinases
Placenta
Neoplasms
Fetus
Drug Therapy
Active Biological Transport
Therapeutics
Fetal Development
Counseling
Monoclonal Antibodies
Safety

Keywords

  • Abortion
  • Biological agents
  • Cancer during pregnancy
  • Malformation
  • Monoclonal antibodies
  • Safety
  • Targeted agents
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Targeted agents for cancer treatment during pregnancy. / Lambertini, Matteo; Peccatori, Fedro A.; Azim, Hatem A.

In: Cancer Treatment Reviews, Vol. 41, No. 4, 01.04.2015, p. 301-309.

Research output: Contribution to journalArticle

Lambertini, Matteo ; Peccatori, Fedro A. ; Azim, Hatem A. / Targeted agents for cancer treatment during pregnancy. In: Cancer Treatment Reviews. 2015 ; Vol. 41, No. 4. pp. 301-309.
@article{ea614cc59a7343df9f07c4d31b651f7d,
title = "Targeted agents for cancer treatment during pregnancy",
abstract = "The last decade has witnessed important advances in the field of managing cancer during pregnancy. However, still limited data is available on the safety of administering targeted agents in pregnant cancer patients. Given the increasing use of targeted agents in clinical practice, it is becoming vital to properly understand how far they can be used in a pregnant patient without compromising the outcome of the fetus. Unlike chemotherapy, monoclonal antibodies are large molecules that require active transport via the placenta to reach the fetus. On the other hand, similarly to chemotherapy, small molecules like tyrosine kinase inhibitors (TKIs) can cross the placenta throughout the pregnancy period.The majority of targeted agents have worrying preclinical data discouraging their use during pregnancy. Multi-TKIs are of particular concern given their potential interference with other vital physiological functions that could be necessary in fetal development. Yet this does not mean that all targeted agents should be avoided completely during pregnancy. The current review provides a critical evaluation on all targeted agents that are currently in clinical use and provides a guide in order to help clinicians counseling their pregnant cancer patients.",
keywords = "Abortion, Biological agents, Cancer during pregnancy, Malformation, Monoclonal antibodies, Safety, Targeted agents, Tyrosine kinase inhibitors",
author = "Matteo Lambertini and Peccatori, {Fedro A.} and Azim, {Hatem A.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.ctrv.2015.03.001",
language = "English",
volume = "41",
pages = "301--309",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Targeted agents for cancer treatment during pregnancy

AU - Lambertini, Matteo

AU - Peccatori, Fedro A.

AU - Azim, Hatem A.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - The last decade has witnessed important advances in the field of managing cancer during pregnancy. However, still limited data is available on the safety of administering targeted agents in pregnant cancer patients. Given the increasing use of targeted agents in clinical practice, it is becoming vital to properly understand how far they can be used in a pregnant patient without compromising the outcome of the fetus. Unlike chemotherapy, monoclonal antibodies are large molecules that require active transport via the placenta to reach the fetus. On the other hand, similarly to chemotherapy, small molecules like tyrosine kinase inhibitors (TKIs) can cross the placenta throughout the pregnancy period.The majority of targeted agents have worrying preclinical data discouraging their use during pregnancy. Multi-TKIs are of particular concern given their potential interference with other vital physiological functions that could be necessary in fetal development. Yet this does not mean that all targeted agents should be avoided completely during pregnancy. The current review provides a critical evaluation on all targeted agents that are currently in clinical use and provides a guide in order to help clinicians counseling their pregnant cancer patients.

AB - The last decade has witnessed important advances in the field of managing cancer during pregnancy. However, still limited data is available on the safety of administering targeted agents in pregnant cancer patients. Given the increasing use of targeted agents in clinical practice, it is becoming vital to properly understand how far they can be used in a pregnant patient without compromising the outcome of the fetus. Unlike chemotherapy, monoclonal antibodies are large molecules that require active transport via the placenta to reach the fetus. On the other hand, similarly to chemotherapy, small molecules like tyrosine kinase inhibitors (TKIs) can cross the placenta throughout the pregnancy period.The majority of targeted agents have worrying preclinical data discouraging their use during pregnancy. Multi-TKIs are of particular concern given their potential interference with other vital physiological functions that could be necessary in fetal development. Yet this does not mean that all targeted agents should be avoided completely during pregnancy. The current review provides a critical evaluation on all targeted agents that are currently in clinical use and provides a guide in order to help clinicians counseling their pregnant cancer patients.

KW - Abortion

KW - Biological agents

KW - Cancer during pregnancy

KW - Malformation

KW - Monoclonal antibodies

KW - Safety

KW - Targeted agents

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84926247650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926247650&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2015.03.001

DO - 10.1016/j.ctrv.2015.03.001

M3 - Article

C2 - 25795021

AN - SCOPUS:84926247650

VL - 41

SP - 301

EP - 309

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 4

ER -